We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+9.87%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$469K
(-0.16%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-9.03%
Top 10 Holdings %
Top 10 Hldgs %
39.8%
Holding
92
New
15
Increased
30
Reduced
32
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$9.95M |
| 2 |
Encompass Health
EHC
|
+$8.69M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$5.99M |
| 4 |
Biogen
BIIB
|
+$5.15M |
| 5 |
Pfizer
PFE
|
+$4.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$10.6M |
| 2 |
Globus Medical
GMED
|
+$10.3M |
| 3 |
Merck
MRK
|
+$10.2M |
| 4 |
Becton Dickinson
BDX
|
+$8.54M |
| 5 |
STJ
St Jude Medical
STJ
|
+$7.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.39% |
| 2 | Financials | 3.11% |
| 3 | Technology | 0.63% |
| 4 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Teva Pharmaceuticals
TEVA
$40.8B
| $21.7M | 7.24% |
330,033
+96,933
| +42% | +$5.99M |
|
|
MNK
2
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $16.5M | 5.53% |
221,529
+62,520
| +39% | +$4.21M |
|
|
3
Zimmer Biomet
ZBH
$18.2B
| $13.6M | 4.54% |
136,377
+101,666
| +293% | +$9.95M |
|
|
4
Encompass Health
EHC
$11B
| $12.7M | 4.24% |
457,913
+305,439
| +200% | +$8.69M |
|
5
Medtronic
MDT
$109B
| $10.1M | 3.36% |
130,666
+26,348
| +25% | +$1.98M |
|
|
6
Biogen
BIIB
$30B
| $9.66M | 3.23% |
31,532
+17,920
| +132% | +$5.15M |
|
|
AET
7
DELISTED
Aetna Inc
AET
| $9.3M | 3.11% |
86,015
-14,835
| -15% | -$1.6M |
|
|
BXLT
8
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $8.59M | 2.87% |
220,125
+70,425
| +47% | +$2.45M |
|
9
UnitedHealth
UNH
$376B
| $8.53M | 2.85% |
72,506
-12,294
| -14% | -$1.44M |
|
10
Viatris
VTRS
$20.4B
| $8.44M | 2.82% |
156,020
+47,920
| +44% | +$2.3M |
|
|
SPNC
11
DELISTED
Spectranetics Corp
SPNC
| $8.37M | 2.8% |
555,766
-7,884
| -1% | -$104K |
|
|
STJ
12
DELISTED
St Jude Medical
STJ
| $7.84M | 2.62% |
126,881
-118,645
| -48% | -$7.48M |
|
|
13
Becton Dickinson
BDX
$45.6B
| $7.64M | 2.56% |
50,857
-59,323
| -54% | -$8.54M |
|
|
AGN
14
DELISTED
Allergan plc
AGN
| $7.38M | 2.47% |
23,600
-21,966
| -48% | -$6.54M |
|
|
ESRX
15
DELISTED
Express Scripts Holding Company
ESRX
| $6.97M | 2.33% |
79,727
+3,540
| +5% | +$303K |
|
16
McKesson
MCK
$100B
| $6.23M | 2.08% |
31,571
+22,402
| +244% | +$4.23M |
|
|
17
Thermo Fisher Scientific
TMO
$213B
| $5.98M | 2% |
42,145
-79,429
| -65% | -$10.6M |
|
18
AbbVie
ABBV
$443B
| $5.17M | 1.73% |
87,300
+70,900
| +432% | +$4.08M |
|
19
Abbott
ABT
$183B
| $5.16M | 1.73% |
114,984
-1,621
| -1% | -$71.6K |
|
20
Stryker
SYK
$125B
| $5.15M | 1.72% |
55,460
-34,826
| -39% | -$3.33M |
|
21
Boston Scientific
BSX
$69.5B
| $5.09M | 1.7% |
276,098
+21,398
| +8% | +$383K |
|
22
Centene
CNC
$30.7B
| $4.88M | 1.63% |
148,276
-14,452
| -9% | -$428K |
|
|
NVRO
23
DELISTED
NEVRO CORP.
NVRO
| $4.59M | 1.54% |
68,052
-37,248
| -35% | -$1.99M |
|
24
HCA Healthcare
HCA
$87.2B
| $4.48M | 1.5% |
66,225
-37,800
| -36% | -$2.64M |
|
25
Standard BioTools
LAB
$340M
| $4.36M | 1.46% |
403,290
-94,478
| -19% | -$928K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, Endurant Capital Management held 92 positions worth $299M, down 0.16% from $300M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Endurant Capital Management withdrew a net $27M in Q4 2015, closing 15 positions and reducing 32 holdings. Its most notable exit was CR Bard Inc., an estimated $3.71M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials and Technology.
Against the trend, Endurant Capital Management opened a new position in Pfizer worth $4.17M.
- Endurant Capital Management's largest Q4 2015 buy was Pfizer: 136,282 shares worth $4.17M.
- Endurant Capital Management added most to Zimmer Biomet in Q4 2015, an estimated $9.95M increase.
- Endurant Capital Management's biggest Q4 2015 reduction was Thermo Fisher Scientific, cutting an estimated $10.6M.
- Endurant Capital Management fully exited CR Bard Inc. in Q4 2015, selling an estimated $3.71M.
- Endurant Capital Management's ten largest holdings make up 40% of its $299M portfolio in Q4 2015.
- Endurant Capital Management opened 15 new positions and closed 15 in Q4 2015.
- Endurant Capital Management's portfolio value fell 0.16% quarter-over-quarter to $299M.
Based on Endurant Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.